From MAMA Grand Prize to Billboard #1 — ENHYPEN''s Two-Year Rise, by the Numbers
One grand prize. 1.65 million first-day sales. Billboard Artist 100 #1. A closer look at the numbers ENHYPEN stacked up in 2025 and 2026.
From MAMA Grand Prize to Billboard #1 — ENHYPEN's Two-Year Rise, by the Numbers
1.65 million first-day sales. Billboard Artist 100 #1. 30M MV views in 10 days.
The numbers behind ENHYPEN's trajectory.
Table of Contents
In the third week of January 2026, when Billboard dropped its weekly charts, screenshots started flying around the K-pop community. ENHYPEN had hit #1 on the Billboard Artist 100 — and if you're wondering how many Korean groups have ever landed that spot, the answer is: you can count them on one hand.
But that wasn't even the full story. That same week, their first-day sales (called chodon in K-pop — the number of physical copies sold on release day) came in at 1,652,560 units, higher than any other K-pop album released in January 2026. The raw number might not mean much on its own, but the context is where it gets interesting.
To understand where these numbers came from, you have to go back to 2025.
2025: MAMA Grand Prize, Coachella, 676K on Tour
In December 2025, at the MAMA Awards (Mnet Asian Music Awards — one of the biggest year-end award shows in K-pop), ENHYPEN took home three trophies including the Fans' Choice of the Year grand prize. Winning the top award in their fifth year after debut. Inside the fandom, it felt like overdue recognition. Outside of it, this was around the time people started saying, "Wait, ENHYPEN is really blowing up right now."
The live side of things was just as strong. In April, they performed at Coachella — still a significant milestone for any K-pop act, since it signals crossover credibility in the Western market. Later that year, their WALK THE LINE world tour sold out across North America and Europe, wrapping up with a total of 676,000 attendees. Billboard Boxscore ranked it #4 on its list of the most successful K-pop tours of 2025 — and that ranking is based on revenue, not just headcount, which makes it a different kind of benchmark.
Their album chart performance had been climbing steadily too. Here's how their Billboard 200 debuts looked from 2022 onward:
| Album | Released | Billboard 200 Peak |
|---|---|---|
| MANIFESTO : DAY 1 | 2022 | #6 |
| DARK BLOOD | 2023 | #4 |
| ORANGE BLOOD | 2023 | #4 |
| ROMANCE : UNTOLD | 2024 | #2 (Triple Million-Seller) |
| DESIRE : UNLEASH | 2025 | #3 |
A steady climb, then a jump to #2 in 2024 — and that album went on to become a triple million-seller, meaning it crossed 3 million total copies sold. Sustaining that kind of upward momentum across three years is rarer than it might look.
THE SIN : VANISH — What 1.65M First-Day Sales Actually Means
On January 16, 2026, ENHYPEN dropped their 7th mini album: "THE SIN : VANISH."
'THE SIN' is a vampire universe. The story follows two lovers — one human, one vampire — living in a world where their relationship is forbidden, forced to go on the run. K-pop lore and worldbuilding can sometimes feel like a barrier to entry, but this one's pretty accessible: two people running from the world, a forbidden love, and all the tension that comes with it. Think "secret romance meets chase thriller."
1,652,560 first-day sales. 2,075,056 first-week sales. Hanteo Chart (South Korea's main real-time physical sales tracker) #1. iTunes #1 worldwide. And yes, that Billboard Artist 100 #1 came from this album.
That last one was genuinely surprising. The Billboard Artist 100 is a composite chart that factors in streaming, album sales, and overall popularity — and landing #1 means you were the most talked-about artist in the US that week. The reason K-pop groups don't top it more often isn't that it's hard to sell albums globally; it's that the chart weights US-based consumption specifically. Big international numbers don't automatically translate. THE SIN : VANISH debuted at #2 on the Billboard 200 and held its spot on the chart for four consecutive weeks.
Knife: 30 Million Views in 10 Days
The title track "Knife" deserves its own mention.
Hip-hop and trap beats layered under sharp synth textures — it captures the tension of fleeing through the night that runs through the album's vampire storyline. The MV crossed 30 million views in just 10 days and hit #1 on YouTube's Global Trending chart. To put the speed in perspective: most K-pop MVs take several weeks to reach 10 million views. Thirty million in ten days is a genuinely different pace.
▶
ENHYPEN 'Knife' Official MV | Watch on YouTube
One thing that stood out: the MV comment section was full of people dissecting the vampire lore — including plenty of non-fans who got pulled in by the visuals and ended up asking "wait, what's the story here?" That kind of curious-newcomer engagement is usually a good sign.
March: Hitting the Big Screen
This one is happening right now. On March 5 and 7, 2026, ENHYPEN's concert film will be showing in movie theaters around the world for a limited run.
"ENHYPEN [WALK THE LINE SUMMER EDITION] IN CINEMAS" combines footage from their Japan summer tour with behind-the-scenes content and day-in-the-life moments with the members. It's partly an extension of a tour that already drew 676,000 people — and partly a first-time entry point for fans who missed out. Releasing a concert film in global theaters isn't something every K-pop group gets to do; it tends to require both scale and a level of trust from distributors that takes years to build.
What the Numbers Are Saying
MAMA Grand Prize. Coachella. 676K on tour. 1.65 million first-day sales. Billboard Artist 100 #1. 30 million MV views in 10 days.
There's one thread connecting all of it. They started at #6 on the Billboard 200 in 2022 and climbed a little higher with every release. In January 2026, they stood at the top of the Artist 100 for the first time. They didn't rely on album sales alone — they built their fanbase through live performances and immersive storytelling, and that investment came back in the form of chart results.
Numbers aren't everything. But they don't lie. These ones paint a pretty clear picture of which direction ENHYPEN has been moving over the past three years.